Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials

Go back to Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
Merck & Co. (NYSE: MRK) Delayed: 140.53 -1.29 (0.91%)
Previous Close $141.82    52 Week High $65.46 
Open $140.00    52 Week Low $47.97 
Day High $142.40    P/E 95.60 
Day Low $139.21    EPS $1.47 
Volume 4,115,328